eMedicine Specialties > Obstetrics and Gynecology > Reproductive Endocrinology and Infertility

Anovulation

Armando E Hernandez-Rey, MD, Consulting Staff, Fertility and IVF Center of Miami
Krystene I Boyle, MD, Staff Physician, Department of Obstetrics and Gynecology, University Hospital of New Jersey Medical School; Cassandra Blot, MD, Staff Physician, Department of Obstetrics and Gynecology, Robert Wood Johnson University Hospital; Peter G McGovern, MD, Associate Professor and Director, Department of Obstetrics, Gynecology, and Women's Health, Division of Reproductive Endocrinology and Infertility, UMDNJ-New Jersey Medical School

Updated: Jan 15, 2008

Introduction

Background

Ovulation is the result of a maturation process that occurs in the hypothalamic-pituitary-ovarian (HPO) axis and is orchestrated by a neuroendocrine cascade terminating in the ovaries. Any alteration results in a failure to release a mature ovum, leading to anovulatory cycles. Anovulation may manifest in a variety of clinical presentations, from luteal insufficiency to oligomenorrhea.

Anovulation is a not a disease but a sign, in much the same way that polycystic ovaries are the manifestation of a much larger disease process.

Pathophysiology

Luteinizing hormone (LH) is the physiologic signal necessary for ovulation, which is mediated by a concomitant surge in estrogen. As the follicle grows through accumulation of follicular fluid, the cohort of granulosa cells acquire the necessary receptors to respond to LH with increased formation of cyclic adenosine monophosphate (cAMP). Generally speaking, approximately 16-24 hours after the LH peak, ovulation occurs with the extrusion of a mature graafian follicle and the formation of the corpus luteum.¹ These events are the culmination of a well-coordinated interplay between hormones and their appropriate receptors and proteolytic enzymes and prostaglandins acting in concert with one another, all directed by the HPO axis.

The system is so sensitive that even the slightest alteration in any of these factors can disrupt its fluidity and lead to anovulation.

When problems arise at any of the many different levels involved in the normal menstrual cycle, it is sometimes helpful to separate the levels by organ system. The hypothalamus and the anterior pituitary can be considered the neuroendocrine components by virtue of their proximity to each another, while the ovaries are a separate compartment. The third aspect that can be defective is the signaling process that occurs between these 2 areas.¹

The initial stimulus must come from the hypothalamus in the form of gonadotropin-releasing hormone (GnRH); this decapeptide must be secreted in a pulsatile fashion within a critical range. For example, sexual maturity is not attained until the onset of regular ovulatory cycles, which may take months to years to occur. This maturation process is orchestrated by a neuroendocrine cascade and modified by autocrine and paracrine events in the ovaries, in which GnRH is the principal mediator.²

Any alteration in the GnRH pulse generator alters the hormonal milieu necessary for gonadotropin secretion and eventual response at the level of the ovary. Several entities (eg, hyperprolactinemia) are known to cause this type of dysregulation. Increasing levels of prolactin can cause a woman to progress from a deficient luteal phase to overt amenorrhea, usually associated with complete GnRH suppression. More common causes of dysregulation include stress, anxiety, and eating disorders, which are also associated with an inhibition of normal GnRH pulsatility through excessive hypothalamic activity of corticotrophin-releasing hormone and stimulation of beta-endorphins.³

How polycystic ovary syndrome (PCOS) is associated with anovulatory cycles has not been completely elucidated. Two associations with this disease entity are theorized to be at least somewhat responsible for its development. The first is the persistent elevation of LH levels in these patients; the second is the apparent arrest of antral follicle development at the 5- to 10-mm stage and consequent failure to enter the preovulatory phase of the cycle.⁴ This evidence indicates that the disturbance is mainly a central defect that initiates the cascade of events leading to its onset.

Similarly, any condition, whether primary or secondary, that results in either a persistent elevation or an insufficient attainment of estrogen levels can inhibit ovulation through a disruption of the mechanisms that induce the LH surge. In order to achieve the corresponding changes within the cycle, estradiol levels must rise and fall appropriately.¹

Frequency

United States

Almost all women experience anovulatory cycles at some point in their reproductive lives. Yet, to attempt to determine the frequency of chronic anovulation in the general population is quite difficult because of underreporting. Estimates of chronic anovulation rates range from 6-15% of women during the reproductive years.

Interestingly, an article by Rasgon introduced a certain subset of the population as being at an increased risk for anovulatory disorders, stating that reproductive endocrine disorders, such as PCOS, hypothalamic amenorrhea, premature menopause, and hyperprolactinemia, are reportedly more common in women with epilepsy than in the general female population. The article further elaborates on the frequency of PCOS in patients who endure epilepsy independent of the use of antiepileptic therapy.⁵

Mortality/Morbidity

Morbidities associated with chronic anovulation include hyperinsulinemia, insulin resistance, early onset of type 2 diabetes mellitus, dyslipidemia, cardiovascular disease, and infertility.

Race

In one study, the frequency of anovulation was greater among white women (9 of 63 [14.3%]) than black women (4 of 56 [7.1%]) or Hispanic women (7 of 102 [6.9%]), although these differences were not statistically significant.⁶

Sex

Obviously, anovulation occurs only in women of reproductive age.

Age

Anovulation is physiologic at the extremes of reproductive age. During menarche, absence of ovulation is due to immaturity of the HPO axis, leading to an uncoordinated secretion of GnRH (pulsatility).

During perimenopause, ovarian factors and a dysregulation of feedback mechanisms are responsible.

When anovulation occurs outside of the perimenarchal or perimenopausal years, extrinsic and intrinsic causes must be excluded.

Clinical

History

• Past medical and surgical history - Infections, history of pelvic surgery, anatomic anomalies, previous diagnosis of chromosomal abnormalities, past history of dilatation and curettage (history of postsurgical changes in menstrual flow, including amenorrhea and Asherman syndrome)
• Past family history - Mother and/or sisters with similar symptoms
• History of pubertal development - Onset of menarche, pubarche, growth spurt
• Detailed history of the menses - Current frequency, regularity or irregularity, length, and quantity of uterine bleeding
• Past reproductive history - Pregnancy losses; antepartum, intrapartum, and postpartum complications, including dilatation and curettage, because of retained products of conception after an early pregnancy loss and after a normal vaginal delivery (see past surgical history)
• Past and current sexual activity - Number of partners; history of sexually transmitted diseases, painful intercourse, and vaginal symptoms (eg, burning, postcoital bleeding)
• Contraceptive practices - Methods of contraception and duration of use, such as type of oral contraceptives and intrauterine devices (IUDs), including progestin-IUDs
• Dietary history - Recent weight gain or weight loss
• Medications (past and present)
• Psychologic history -Depression, emotional lability, anxiety, stress (including status of current relationships)
• History of previous malignancies (eg, craniopharyngioma, leukemia, Hodgkin disease) and treatments received (eg, radiation, alkylating chemotherapeutic agents)
• Review of symptoms
  • Headaches
  • Visual disturbances
  • Changes in hair distribution or appearance
  • Deepening of voice
  • Breast secretions (unilateral, bilateral)

Physical

• Vital signs
• General - Voice, affect, presentation (eg, disheveled, well-groomed)
• Dermatologic - Facial acne (cystic), acanthosis nigricans (velvety dark patches usually found on the lateral aspects of the neck, axillae, and inner aspects of the thighs), stigmata of hepatic disease (telangiectasia, caput medusae), violaceous striae usually in the flanks (Cushing syndrome)
• Head, eyes, ears, nose, and throat
  • Head - Hair distribution (male pattern baldness), facial hair, cushingoid facies
  • Eyes - Exophthalmos, visual acuity and visual fields (ruling out bitemporal hemianopsia)
  • Ears - Enlarged, disproportionate (acromegaly)
  • Nose - Enlarged (disproportionate to rest of face [acromegaly]), anosmia (scent of orange peels [Kallmann syndrome])
  • Throat - Webbing of neck (Turner syndrome [ie, remnants of cystic hygroma]), carotid bruits, thyromegaly
• Breasts/chest - Marshall-Tanner staging, areola (protuberance, pigmentation), secretions, shape of breasts (cylindrical as in exogenous estrogen exposure), decrease in breast size (androgen exposure), presence of shield chest (Turner syndrome)
• Heart/lungs - Murmurs
• Abdomen - Linea alba, infraumbilical hair distribution, waist/hip ratio, striae (as above)
• Genitourinary - Mons pubis, Marshall-Tanner staging, male-female escutcheon, absence of pubic hair (androgen insensitivity syndrome), vulvar skin (hypoestrogenized), vulvovaginal mucosa (hypoestrogenized), clitoris (clitoral index, >35 mm²), bimanual examination to exclude ovarian/adnexal masses, age-appropriateness of genitalia
• Extremities - Presence of lanugo (anorexia) versus male hair characteristics (hirsutism)

Causes

Volumes have been written on the different clinical entities associated with anovulation. Based on serum gonadotropins and ovarian hormones, clinicians are usually able to discern whether the ovulatory dysfunction is of central or ovarian origin. In the presence of PCOS, hormone levels are usually within the reference range, but they are accompanied by a wide array of clinical manifestations that may signal the presence of this disorder. The following describes the most important causes of anovulation and elaborates on their clinical and biochemical manifestations:

• Polycystic ovary syndrome: PCOS is the most common endocrinopathy in women of reproductive age, with a prevalence of approximately 4-6%. Its cardinal features are hyperandrogenism and polycystic ovaries.⁷ Clinically, PCOS is characterized by menstrual irregularities, hyperandrogenism, hyperinsulinemia, and long-term metabolic disturbances, such as diabetes mellitus, cardiovascular disease, and dyslipidemias.⁸ During the Rotterdam Conference of 2003, a revision of the diagnostic criteria the US National Institutes of Health conference initially proposed in 1990 was made to include the findings of polycystic ovaries:
  • 2003 consensus statement on PCOS
    • Oligo-ovulation or anovulation - Clinical and/or biochemical signs of hyperandrogenism and exclusion of other etiologies (eg, congenital adrenal hyperplasia [CAH], androgen-secreting tumors, Cushing syndrome)
    • Polycystic ovaries - Presence of 12 or more follicles in each ovary measuring 2-9 mm in diameter and/or increased ovarian volume greater than 10 mL⁹ (see Media file 1)
  • Anovulation in patients with PCOS
    • Because of the disparity between follicular growth and steroidogenesis, Franks et al have proposed that a premature activation of LH-induced mitotic arrest, which occurs normally at the onset of the midcycle LH surge, is responsible for the ovulatory dysfunction noted in patients with PCOS.⁴ Therefore, a combination of elevated LH levels with enhanced LH action may be responsible not only for the arrested growth of the follicles but also the increased production of estradiol.^10,4
    • Franks et al further hypothesize that these mechanisms may be intimately related to overproduction of cAMP at the level of the granulosa cell, whereby follicular arrest occurs simultaneously with excess androgen production.⁴
  • Hyperinsulinemia and insulin resistance
    • Insulin resistance, independent of obesity, has also been described as being pathognomonic of PCOS.¹¹ Mechanisms have been proposed to account for the excess insulin production by the pancreas: (1) decreased insulin binding, (2) decreased insulin receptor numbers (down-regulation), and (3) postreceptor failures due to serine phosphorylation and eventual increase in pancreatic beta-cell stimulation.
    • Regardless of the cause, insulin resistance is predominantly seen peripherally, at the level of skeletal muscle, where 85-90% of circulating insulin is used. The compensatory hyperinsulinemia that occurs contributes to androgen excess by directly stimulating androgen production in the adrenal cortex and through a direct effect on granulosa cells and a simultaneous decrease of sex hormone–binding globulin (SHBG) in the ovaries.¹²
  • Obesity
    • A centripetal, or apple-shaped, distribution of adipose tissue (waist-hip ratio, >0.88) is associated with a greater risk for hypertension, diabetes, and dyslipidemia.
    • Although many of the metabolic abnormalities can be alleviated with weight loss, they are still present. PCOS is neither caused by obesity nor cured by weight reduction.¹³
  • Hirsutism
    • Hirsutism is the excessive growth of terminal hair, usually in a midline distribution or male-type pattern. The condition is characterized by a response of the pilosebaceous unit to androgens, causing a transformation of vellus to terminal hair in androgen-dependent areas.¹⁴ Hirsutism is classified into the following groups: (1) idiopathic, (2) drug-induced, and (3) due to androgen excess. Most cases of hirsutism result from a combination of mildly increased androgen production and increased skin sensitivity to androgens. Cases that are not androgen-dependent (eg, those caused by medications or familial hypertrichosis) are best diagnosed by physical examination.
    • Approximately 95% of women with androgen-dependent hirsutism have both adrenal and ovarian causes. Adrenal, ovarian, and exogenous androgen exposure each account for approximately 1% of cases. The most common cause of hirsutism is PCOS, which manifests as oligomenorrhea, plus hyperandrogenism often accompanied by insulin resistance. Additionally, different cultures and races tend to have or display hair in different amounts and locations. These patients are generally classified into the first group in the presence of normal levels of circulating androgens.
    • Many drugs can induce hyperthecosis. These agents are divided into those that have androgenic activity and those that have nonandrogenic activity.
    • If excess androgens are the primary cause of the hirsutism, androgen receptors are found in the anagen (active) phase in the follicles' dermal papillae and associated sebaceous glands, where stimulation is provided by the more potent androgens testosterone and dihydrotestosterone. In excessive amounts, they cause hirsutism, except on the scalp, where androgenic alopecia is induced.¹⁵
    • A clinical tool that offers an objective assessment of the hirsute patient is the modified Ferriman-Gallwey scale proposed by Hatch and coworkers. It takes into account 9 of the 11 sites originally described, each receiving a score of 0-4 (maximum). A score of 8 or more is considered significant.
    • The presence of hirsutism in conjunction with other signs of virilization should alert the physician to the possibility of androgen-producing tumors of adrenal or ovarian origin.
• Chronic anovulation
  • Chronic anovulation with estrogen present can occur in a variety of endocrine disorders. It can occur in women with PCOS and other functional abnormalities, including those with Cushing syndrome, hyperthyroidism, hypothyroidism, late-onset adrenal hyperplasia resulting from 21-hydroxylase deficiency, 11-alpha-hydroxylase deficiency, or 3-beta-hydroxysteroid dehydrogenase deficiency.
  • Chronic anovulation may also involve tumors of the ovary, including granulosa-theca cell tumors, Brenner tumors, cystic teratomas, mucinous cystadenomas, and Krukenberg tumors. These tumors secrete excess estrogen or androgens that undergo aromatization in extraglandular sites.
• Cushing syndrome
  • Cushing syndrome is characterized by hypercortisolism (see Media file 2). Its clinical manifestations encompass a spectrum of symptoms, the severity of which is often influenced by the presence or absence of androgen excess (see Media file 3). Progressive obesity and abnormal waist/hip ratio are not uncommon, although the limbs are often spared. Frequently, patients experience proximal muscle weakness and cannot rise from a sitting position. Patients can also be hypertensive as a result of mineralocorticoid excess.
  • Normally, cortisol-releasing hormone and hypothalamic factors are released into the hypophyseal portal blood and carried to the anterior pituitary, where they stimulate the release of adrenocorticotropic hormone (ACTH). In Cushing disease, the increased plasma ACTH concentrations stimulate increased adrenocorticoid secretion, thus inhibiting hypothalamic corticotropin-releasing hormone (CRH) secretion and other factors from the pituitary. This aberration in the cycle, as well as changes in secretory patterns, are thought to influence the mechanisms involved in ovulatory function. Although the exact mechanisms have not been elucidated, it is believed that hypercortisolism and adrenal hyperandrogenism suppress gonadotropin secretion with impaired LH response to GnRH.
• Adrenal insufficiency
  • Adrenal insufficiency can be due to a variety of causes, including deficient hypothalamic secretion of CRH, deficient pituitary secretion of ACTH, or destruction of the adrenal cortex (Addison disease, primary adrenal insufficiency).
  • Adrenal androgen deficiency results in loss of axillary and pubic hair in women and decreased libido. Women with autoimmune adrenal insufficiency are at increased risk of premature ovarian failure and anovulation.
• Congenital adrenal hyperplasia
  • CAH encompasses a group of autosomal recessive disorders caused by an inherited deficiency of enzymes involved in cortisol synthesis in the adrenal cortex.
  • These disorders, listed in decreasing order of frequency, include a deficiency of 21-hydroxylase, 11-alpha-hydroxylase, and 3-beta-hydroxysteroid dehydrogenase. Hyperandrogenism induces a disruption of the HPO axis and consequently leads to menstrual irregularities or anovulatory cycles.
• Hyperthyroidism and hypothyroidism
  • Hyperthyroidism
    • Some women experience oligomenorrhea. Increased thyroid hormone levels raise SHBG production and therefore serum levels, reflecting increased tissue response to these hormones. Total estrogen and testosterone circulating levels are also increased.
    • The levels of active or free fractions of these sex steroids are often reduced. Treatment of hyperthyroidism results in regular ovulatory menstrual cycles and fertility. Mid luteal phase progesterone levels in thyrotoxic women improve after treatment.
  • Hypothyroidism
    • Women with hypothyroidism often experience the spectrum of menorrhagia and metrorrhagia. Patients with hypothyroidism have reduced levels of SHBG and decreased levels of circulating estrogens and testosterone. Follicle-stimulating hormone (FSH) and LH levels are also reduced. Hypothyroidism can cause aberrations in coagulation. It is believed that a hypothyroid state leads to decreased levels of factors VII, VIII, IX, and XI. Hypothyroidism is the most common endocrinologic condition associated with anovulation.
    • In addition, hypothyroidism alters steroid metabolism and clearance, which may lead to endometrial dysfunction. This evidence supports the fact that menorrhagia is a symptom of hypothyroidism. These symptoms are easily treated with thyroid hormone replacement. Hypothyroidism leads to increased levels of thyroid-releasing hormone and therefore increased levels of thyroid-stimulating hormone (TSH [ie, thyrotropin]) and prolactin. Hyperprolactinemia from long-standing primary hypothyroidism may be responsible for varying degrees of ovulatory dysfunction.
• Hyperprolactinemia
  • Prolactin excess manifests clinically as infertility, oligomenorrhea, and amenorrhea. The mechanism seems to involve the inhibition of pituitary gonadotropins via suppression of GnRH pulsatility. As a result of this inhibition, serum gonadotropin levels are significantly decreased, causing secondary hypogonadism. Mild hyperprolactinemia may cause infertility, even in the presence of a regular menstrual cycle, while elevated levels of prolactin may cause galactorrhea.
  • Patients with hyperprolactinemia must always have a complete history and physical examination to rule out easily correctable causes of hyperprolactinemia. Some of these causes include medication usage (eg, exogenous estrogens, neuroleptics, antidepressants, some antipsychotic medications). MRI should be obtained to rule out a mass lesion in the hypothalamic-pituitary region (see Media file 4). Usually, imaging is not warranted unless levels surpass 100 ng/mL after a negative pregnancy test result. Normalization of prolactin levels through the adjustment of current medications or addition of bromocriptine restores ovulation and fertility.
• Eating disorders and aggressive exercise habits
  • Anorexia is defined as a serious, usually chronic psychiatric disorder of an indolent nature that can be life-threatening if unrecognized. The condition is characterized by a patient's inability to maintain a weight of at least 85% of her ideal body weight. Other essential features of the disorder include an intense fear of gaining weight, a distorted body image (body dysmorphic syndrome), and amenorrhea.
  • Below-average body weight is not in itself enough to cause amenorrhea; the numerous mechanisms intimately related to profound weight loss are also factors. Frisch and McArthur have suggested that a minimum of 17% body fat is required for the initiation of menses, and at least 22% body fat is necessary for menstrual cyclicity.¹⁶ Leptin, a serum hormone secreted by adipose tissues in proportion to total body lipid stores, has recently received much attention for its role in the pathogenesis of weight and menstrual control in these patients.
  • A diurnal secretion pattern has been established in women of reproductive age who have a normal body mass index (BMI). Athletes with exercise-induced amenorrhea exhibit leptin levels similar to those of prepubertal girls and consequently lose the diurnal release pattern. Andrico, et al demonstrated that leptin levels are significantly lower in patients with functional hypothalamic amenorrhea compared with those of controls who were matched for both age and weight.¹⁷ These investigators suggest that energy balance can interfere with the ratios of body weight to leptin and BMI to leptin in functional hypothalamic amenorrhea.
  • The consequences of exercise-induced amenorrhea are similar to those of estrogen deficiency. These patients are at an increased risk of osteopenia and, eventually, osteoporosis if not treated expeditiously. Vaginal atrophy and infertility issues are generally the rule. A multidisciplinary approach is therefore necessary when treating these patients in order to address underlying issues and physical manifestations.
  • Amenorrhea is a consequence of multiple alterations in female hormonal pathways. Anorexic women show a 24-hour pattern of FSH and LH similar to that observed in prepubescent children. They may also exhibit altered ACTH levels and characteristically low triiodothyronine (T3) levels.
  • The mechanisms involved in amenorrhea caused by excessive exercise or anorexia nervosa are not well understood. However, links seem to exist among malnutrition, chronic disease, and hormonal alterations. Excessive levels of endogenous opioids, with a concomitant increase in CRH secretion, inhibit GnRH release as well. Patients can expect an increased risk of infertility, vaginal and breast atrophy, and osteopenia.
  • Bulimia nervosa is a form of anorexia in which a woman consumes large amounts of food in order to induce vomiting, otherwise known as the binge-and-purge cycle. Fluctuations or extreme weight loss are not common. However, these patients usually experience menstrual irregularities or anovulatory cycles. Commonly, they have halitosis and dental caries. They may also exhibit strange behavior when eating in a group setting. Bulimic patients usually prefer to eat during times that do not coincide with those of other members of the household. The pathophysiology of anovulation in bulimic women is very similar to that of anorexic women, although the neuroendocrine disturbances are significantly milder than in anorexia. LH levels are reduced because of a blunting of the GnRH pulse generator, which leads to the menstrual disturbances commonly observed. Thyroid function is altered, as well as glucose tolerance, with accompanying hypercortisolemia.
• Hypothalamic and pituitary causes
  • Ovulation disorders can result from abnormally low levels of circulating pituitary hormone (hypopituitarism). In normal physiology, ovulation is dependent on the presence of a functioning hypothalamic-pituitary-gonadal axis. The arcuate nucleus within the hypothalamus is composed of a collection of neurons and, when stimulated, releases GnRH into the portal vessels of the pituitary stalk in a pulsatile fashion. GnRH stimulates receptors in the anterior pituitary gland to produce and secrete both LH and FSH. In women, FSH induces maturation of ovarian follicles and eventual production of estrogen, while LH modulates the secretion of androgens from the ovarian theca cells.¹⁸ Estrogen, in turn, produces negative feedback on the pituitary gland. During the midcycle, the estrogen levels in the circulation reach a concentration that causes a positive feedback action on LH secretion. This is called the LH surge.
  • The pituitary gland also has a heightened midcycle response to GnRH. Ovulation occurs as a result of both the LH surge and the midcycle stimulation of the anterior pituitary by GnRH. The presence of GnRH is essential; studies have shown that the administration of a GnRH antagonist to women at midcycle prevents the LH surge. The physiologic capabilities of the hypothalamic GnRH neurons and pituitary gland are subject to disruption by several pathologic entities, including tumors, trauma, and irradiation.
  • Hypothalamic causes include tumors, trauma, and irradiation.
    • Hypothalamic tumors can produce space-occupying lesions that are frequently suprasellar. These tumors can cause abnormally low levels of circulating pituitary hormone by compression of the hypothalamus or pituitary stalk, essentially causing delayed puberty, anovulation, and amenorrhea. Craniopharyngioma is an epithelial cell tumor of nonpituitary origin that accounts for approximately 3% of intracranial neoplasms; it is the most common neoplasm associated with delayed puberty. Craniopharyngiomas arise from remnants of Rathke pouch epithelium and result from incomplete closure of the hypophyseal or craniopharyngeal duct.
    • The clinical features are dependent upon the rate of growth of the tumor and can include visual impairment (ie, bitemporal hemianopsia [70%] due to compression of the optic chiasm), pituitary-adrenal dysfunction (50%), hypothyroidism (25%), somnolence (20%), and diabetes insipidus (10%).^3,19 The evaluation of craniopharyngioma includes the use of CT scanning and MRI. Most lesions are evidenced by enlargement of the pituitary fossa, and suprasellar extension and calcifications are common. Treatment involves surgical extirpation followed by intensive postoperative radiation.
    • A major complication is both hypothalamic and pituitary deficiency despite a conservative surgical approach. After surgical management with tumor irradiation, the 10-year survival rate for people with craniopharyngioma is 70-80%.¹⁹
    • An endodermal sinus tumor is a highly malignant germ cell tumor of the hypothalamus commonly observed in the first and second decades of life. Believed to be derived from antecedents of the yolk sac, it produces alpha-fetoprotein. It is a highly vascular neoplasm that metastasizes early to various regions of the CNS.
    • Hand-Schüller-Christian disease (histiocytosis X) is a rare destructive lesion in children that causes delayed puberty, growth retardation, and diabetes insipidus. These tumors are composed of mononuclear phagocytic cells (histiocytes) that infiltrate and destroy hypothalamic tissue. Clinical features include visual disturbances, hyperprolactinemia, hypopituitarism, anovulation, obesity, and growth retardation. The first presenting symptom is usually growth retardation in a child. Diagnosis is established by biopsy of the lesion, and subsequent treatment is with radiation therapy and growth hormone (GH) replacement.
    • Head injury can cause hypothalamic damage and result in secondary hypopituitarism (ie, a lack of appropriate hypothalamic-releasing factors). The presence of hyperprolactinemia resulting from the traumatic disruption of dopamine inhibition provides evidence of the location of the lesion and helps the clinician differentiate hypothalamic damage from panhypopituitarism in the presence of normal or even low levels of other pituitary hormones.
    • Motor vehicle accidents are thought to cause transection of the hypothalamic-pituitary stalk during forward motion of the head. Transection usually manifests first as diabetes insipidus and then as secondary hypopituitarism and hyperprolactinemia.
    • The hypothalamus is radiosensitive; therefore, external irradiation can cause damage to the hypothalamus and impair its function. In contrast, pituitary cells are relatively radioresistant. Therefore, hypopituitarism that occurs after the administration of external irradiation to the brain typically results from hypothalamic damage.
    • Similarly, irradiation of the head and neck for treatment of nasopharyngeal cancer frequently results in hypopituitarism as early as 1 year after therapy.¹⁹
  • Pituitary causes include trauma and irradiation.
    • The most common cause of pituitary trauma is iatrogenic, occurring during neurosurgery. Other causes include birth trauma, intracranial hemorrhage, fetal asphyxia, and breech delivery, all of which may lead to direct pituitary damage. A sella turcica fracture or pituitary stalk transsection can cause panhypopituitarism and/or diabetes insipidus (if the posterior pituitary is involved). The degree of hypopituitarism varies and typically manifests within a year after trauma has occurred. Many patients do not experience signs of posttraumatic pituitary failure for several decades.
    • Irradiation can cause a significant degree of reproductive dysfunction and anovulation, usually due to hypothalamic damage because pituitary cells exhibit little radiosensitivity. Anticancer treatments are also associated with psychologic stress and weight loss, which can magnify the degree of menstrual dysfunction. The effects of cranial irradiation are dose related, and 70% of women undergoing cranial irradiation experience menstrual irregularities.²⁰
  • Nonneoplastic causes of hypopituitarism include empty sella syndrome, Sheehan syndrome, pituitary apoplexy, and pituitary adenomas.
    • Empty sella syndrome is a benign cause of hyperprolactinemia in 4-16% of women who present with amenorrhea and galactorrhea.¹ It is characterized by an abnormal relationship between the sella turcica and the sellar diaphragm that results in the herniation of the subarachnoid space into the pituitary fossa. A flattening of the pituitary gland and concomitant separation of the gland from the hypothalamus occurs, which can result in the inhibition of GnRH and subsequent anovulation. The degree of flattening of the pituitary also plays a role in the anovulation. Typically, if 90% of the gland is compressed, pituitary failure ensues.
    • The characteristic changes in the relationships between the sellar contents and the suprasellar arachnoid space can be congenital (primary empty sella syndrome) or can result from surgery, radiation, or spontaneous infarction of pituitary adenomas (secondary empty sella syndrome). The diagnosis of empty sella syndrome is usually incidental in patients being evaluated for symptoms of headache and/or an unusual presentation of rhinorrhea. The preferred radiologic imaging modality, MRI, reveals a symmetrically enlarged sella turcica from cerebrospinal fluid (CSF) and demonstrable pituitary flattening with lateral stalk deviation, which can make the fossa initially appear empty.
    • CT-guided intrathecal injection of contrast (metrizamide) can be also be used to demonstrate abnormalities in intracranial CSF distribution. The resultant endocrine abnormalities are varied. Because empty sella syndrome is associated with compression of the infundibular stalk, the disruption of dopamine reaching the pituitary leads to concomitant hyperprolactinemia (5%). Other endocrine abnormalities are rare; however, isolated ACTH deficiency and GH hypersecretion or deficiency have also been described. Treatment for empty sella syndrome is focused on hormone replacement and/or dopamine agonists for hyperprolactinemia in the anovulatory patient.
    • Sheehan syndrome was initially described by Sheehan in 1939 as postpartum pituitary necrosis that results from significant intrapartum or postpartum hemorrhage or shock. It is considered the most common cause of panhypopituitarism in women of childbearing age.²¹ During pregnancy, the anterior pituitary lactotrophs double in size. As a result, the demand for oxygen is greater, and the response to hypotension from hemorrhage is magnified.
    • Rapid hypotension from hemorrhage can interrupt the venous return to the gland and result in necrosis. The initial presenting sign of panhypopituitarism is usually failure to lactate postpartum, followed by amenorrhea, loss of pubic or axillary hair, secondary adrenal insufficiency, anorexia, lethargy, and weight loss. These symptoms are often delayed, and the degree of hypopituitarism varies. Slow clinical progression could suggest other factors involved in the pathogenesis of the disease, such as autoimmunity from antigens released from an infarcted gland.²²
    • The diagnosis is confirmed based on the history and the results from the tests of anterior pituitary reserve: GH, ACTH, prolactin, TSH, LH, and FSH, all of which are found in very low levels. GH deficiency is the most common (90%), followed by ACTH (66%), LH/FSH (65%), and TSH (42%). Posterior pituitary involvement is rare, with central diabetes insipidus occurring in fewer than 5% of cases.²³ The treatment of Sheehan syndrome is based on appropriate hormone replacement. In patients receiving gonadotropins, successful ovulation and eventual pregnancy is common.
    • Pituitary apoplexy is a life-threatening disorder characterized by an acute massive infarction of the pituitary gland; it is a medical emergency that usually results from preexisting, endocrinologically inactive adenomas or tumors of the pituitary gland. The extent of hemorrhage, edema, and infarction of the gland determines the degree of compression of adjacent structures and subsequent neurologic damage. Patients typically present with acute onset of the triad of excruciating, localized retro-orbital headache (95%); nausea and vomiting (65%); and ophthalmoplegia (78%) secondary to compression and stretching of the meninges adjacent to the sella. The tumor expansion can also cause visual field defects and loss of pituitary function, demonstrable by low levels of GH, ACTH, LH/FSH, and TSH.
    • Management of this condition involves immediate administration of cortisol, supportive measures, and surgical intervention and decompression of the sella through a transsphenoidal approach. Studies have shown that patients who undergo surgical decompression within 1 week of the infarction have significant return of their visual defects compared with those undergoing delayed intervention.²⁴ The mortality rate accompanying this condition is high when exogenous cortisol is not administered after recognition of an ACTH deficiency. For patients with anovulation, treatment is supportive. Studies of amenorrheic adolescents who undergo surgical intervention for infarcted microadenomas have shown an 80% postsurgical improvement in endocrine function.²⁵
    • Approximately 10% of all intracranial tumors are pituitary adenomas, with hypersecretion of biologically active hormones. The most common endocrinopathies are acromegaly due to GH excess, Cushing disease due to ACTH excess, and amenorrhea/galactorrhea syndrome due to prolactin excess (prolactinoma). Elevated gonadotropin levels can also result from gonadotropin-secreting pituitary adenomas. However, these rare adenomas are not associated with amenorrhea and usually secrete the beta subunit of FSH and rarely LH. The most common of the pituitary adenomas are prolactinomas.
    • These tumors are rarely life threatening; they result in amenorrhea, galactorrhea, and/or visual defects due to impingement of the optic chiasm from the space-occupying characteristics of the tumor. Previously, prolactinomas were thought to arise from dysregulation of prolactin due to the idiopathic attenuation of hypothalamic dopamine. Recent studies have described a genetic basis for tumor development. Prolactinomas are now thought to arise from proliferation of a single mutated lactotroph (prolactin-producing cell), usually in the lateral wing of the pituitary gland. These tumors have been found to occur in 20% of patients with multiple endocrine neoplasia syndrome, type 1 (MEN 1).²⁶
    • Women who present with amenorrhea/galactorrhea syndrome should undergo laboratory testing for prolactin. levels of more than 250 ng/mL usually indicate prolactin-secreting adenomas, and levels of less than 150 ng/mL are usually secondary to large nonsecreting tumors of the pituitary. MRI or CT scanning with contrast can be used to help confirm diagnosis; however, both techniques have a high false-positive rate because they detect small nonsecreting tumors, cysts, or infarcts. Visual field testing is performed on symptomatic patients.
    • Treatment is reserved for women who experience either effects of tumor size or effects of hyperprolactinemia.²⁶ Most patients with microadenomas (<10 mm) are managed conservatively with serial prolactin levels and follow-up MRI if they become symptomatic with headache or if prolactin levels rise significantly. Macroadenomas (>10 mm) may require more aggressive interventions, such as surgery or irradiation. Medical therapy with dopamine agonist therapy (eg, bromocriptine, cabergoline) can be used in patients with anovulatory menstrual cycles, decreased libido, sexual dysfunction, hirsutism, and osteoporosis. For women desiring fertility, bromocriptine is typically used until the fourth week of pregnancy. Cabergoline is not used for ovulation induction because of the lack of significant data on its possible adverse effects or teratogenicity in pregnancy.
    • Other indications for medical treatment include decreased libido, sexual dysfunction, hirsutism, and galactorrhea.

Differential Diagnoses

Other Problems to Be Considered

Anovulation is a sign and not a disease entity per se; therefore, the purpose of the differential diagnosis is to help distinguish the primary cause of anovulation. Epilepsy and Sheehan syndrome should also be considered, the latter of which should be ruled out with a detailed clinical history and hormonal evaluation.

Workup

Laboratory Studies

• Pregnancy test - Quantitative beta-HCG in all women of reproductive age
• FSH - Important in assessing for premature ovarian failure
• LH - In combination with FSH, helps establish a diagnosis of PCOS (with LH/FSH ratio >2:1)
• Ovarian steroid hormones - Estradiol, progesterone (midluteal)
• TSH - Hypothyroidism
• Prolactin - Hyperprolactinemia
• Glucose - Using a 2-hour glucose tolerance test after 75-g glucose load
• Cortisol with or without ACTH stimulation test - Helps determine presence of adrenal insufficiency
• Total testosterone/free testosterone - In the presence of hirsutism or virilization, can help distinguish ovarian versus adrenal origin
• Dehydroepiandrosterone sulfate (DHEAS) - Hirsutism or virilization of adrenal origin
• 17-Hydroxyprogesterone - CAH
• Pregnenolone - 17-alpha-hydroxylase deficiency
• Workup for autoimmune disorders - May be considered when initial test results are uninformative
  • Complete blood count (CBC)
  • Complete metabolic profile - Electrolytes, albumin, renal function tests, liver function tests
  • Antinuclear antibodies
  • Rheumatoid factor
  • Erythrocyte sedimentation rate
  • C-reactive protein
  • Thyroid antibodies

Imaging Studies

• Ultrasonography - Evaluation of ovaries and endometrium (transvaginal), adrenals (abdominal)
  • Evaluate for the presence of 12 or more follicles in each ovary measuring 2-9 mm in diameter and/or increased ovarian volume greater than 10 mL.⁹
  • A thickened heterogeneous endometrium in the setting of chronic anovulation should prompt suspicion for endometrial hyperplasia regardless of the patient's age.
• Computed tomography scanning - Adrenals (abdominal)
• Magnetic resonance imaging - Pituitary glands, adrenals
• Bone density scanning (ie, dual-energy x-ray absorptiometry [DEXA scan]) - Vertebrae and femur (primarily in hypoestrogenic states)
• Nuclear thyroid scanning - Hot versus cold nodules in the presence of positive physical findings and symptoms

Other Tests

• Karyotype - Usually performed in patients younger than 30 years to rule out presence of Y chromosome (frequency of germ cell tumors in patients >30 y is negligible)
• Galactose-1-phosphate - Galactosemia

Procedures

Endometrial biopsy may be performed to exclude endometrial hyperplasia. An endometrial biopsy should be performed in all women older than 35 years who have irregular uterine bleeding, whether in the presence of anovulatory or ovulatory cycles. Biopsy is also indicated in women younger than 35 years who have a long-standing history of anovulation and concomitant risk factors for endometrial hyperplasia, such as obesity (unopposed estrogenic environment). The most important aspect is that age should not be a factor in deciding whether to perform an endometrial biopsy.

Histologic Findings

Endometrial glands undergo mild architectural changes, including cystic dilation reminiscent of a proliferative endometrium, because of prolonged, excessive endometrial stimulation by estrogens. Unscheduled breakdown of the stroma may also occur, with no evidence of the endometrial secretory activity usually observed as a result of a functioning corpus luteum and subsequent production of progesterone.

Treatment

Medical Care

The medical management of anovulation is complex because it entails initiating a multitiered approach to patient care.

First and foremost, the clinician should be well acquainted with the most common etiologies and able to rule them out, specifically those that can pose serious dangers to a patient's immediate health. Luckily, anovulation usually manifests in a clinical setting geared toward the treatment of chronic diseases and conditions, which provides the precision necessary for an accurate diagnosis. Despite this, patients often have a history of multiple doctor visits because of inadequate or unsuccessful treatment by other physicians secondary to a misdiagnosis. The care of these patients must be tailored to their individual presentations and the specific disease entities responsible for anovulation. A holistic approach, consultation with other specialists, and routine follow-up should be the rule, not the exception.

• Acute bleeding secondary to anovulation
  • Most causes of dysfunctional uterine bleeding respond to either oral or intravenous estrogen. Treatment using the parenteral route can be initiated with estrogen (Premarin) 25 mg IV q4h by accelerating the mitotic activity at the level of the endometrium. If no response is seen after 12-16 hours, suction dilation and curettage is warranted.
  • If the bleeding is not as vigorous, high-dose birth control pills totalling 200 mcg/d of estrogen for 7 days, followed by continuation of oral contraceptives for a minimum of 3 months, has equal efficacy in reestablishing the endometrium.
• Anovulation and amenorrhea
  • Pregnancy test and hormonal studies measuring thyroid function, prolactin levels, and gonadotropin levels should be obtained. These hormonal assays should be followed by a progestational challenge to evaluate the endometrial lining and the presence of a hypoestrogenic state.
  • The first possibility is normal levels with a positive withdrawal bleed. This indicates anovulation and unopposed estrogen stimulation. Treatment is focused on providing progesterone support and cyclicity in the form of oral contraceptives or progestin alone, which is paramount in the prevention of endometrial hyperplasia.
  • If TSH or prolactin levels are elevated, correcting the primary problem is usually enough to attain ovulatory cycles once again.
  • If gonadotropin levels are low or normal, a diagnosis of hypogonadotropic hypogonadism is assumed and a space-occupying lesion versus hypothalamic suppression due to exercise or weight fluctuations (eg, anorexia nervosa, bulimia) must be ruled out. Treatment again focuses on the cause of the suppression.
  • If FSH and LH levels are elevated (hypergonadotropic hypogonadism), the problem is usually related to an absence of inhibitory signals that originate from the ovary under normal conditions; therefore, ovarian failure is presumed. Generally, other signs and symptoms of hypoestrogenism, such as vaginal dryness, emotional lability, and hot flushes due to vasomotor spasm, help confirm the diagnosis. If this occurs before age 30 years, a karyotype is necessary to rule out the presence of a Y chromosome or fragile X premutation. Owing to the high rate of malignant germ cell tumors in this setting, a gonadectomy must be performed immediately. Other considerations are certain autoimmune and infectious processes that can destroy ovarian tissue through infiltration of autoimmune complexes.

Surgical Care

Surgical care is usually indicated to resolve the underlying cause for the anovulation, typically when medical therapy has failed.

Surgery is also indicated in rare cases, such as a macroadenoma of the pituitary with unrelenting growth eliciting severe symptoms (eg, headaches, bitemporal hemianopsia, diplopia). In the event of a benign or malignant neoplasm of ovarian or adrenal origin, exploratory laparotomy, resection, and staging are indicated.

Ovarian drilling and ovarian wedge resection are other surgical modalities used in the treatment of anovulation due to PCOS, with a spontaneous ovulation rate of more than 80% after the procedure.

While dilation and curettage is never first-line therapy for acute bleeding, practitioners are sometimes left with no other option. In even rarer cases, hysterectomy may be the only solution to the profound anemia stemming from acute blood loss.

Bariatric surgery has been advocated in the surgical treatment of severe obesity when accompanied by medical complications in which weight loss could be curative. Gastroplasty, vertical banded gastroplasty, gastric banding, and vertical stapling are commonly used but are less effective than the roux-en-Y gastric bypass. Typically patients with a BMI greater than 40 are candidates for surgery, assuming past attempts at medical treatment have failed, although patients with a BMI of 35-40 and underlying life-threatening medical problem may be considered as well.²⁷

Consultations

• Neurosurgeons - In the presence of a microadenoma unresponsive to medical management with bromocriptine
• Psychiatrists/psychologists - For patients with body dysmorphic disorder and concomitant anorexia nervosa and bulimia
• Nutritionists - For patients with anorexia nervosa and bulimia
• Endocrinologists - When anovulation is due to adrenal disorders such as Cushing syndrome, Addison disease, overt type 2 diabetes mellitus, panhypopituitarism (ie, Sheehan syndrome), refractory thyroid disease
• Gynecologic oncologists/general surgeons - In the case of either an adnexal mass or adrenal mass of benign or malignant origin
• Reproductive endocrinologists and infertility specialists - When fertility is desired in order to appropriately monitor ovulation induction with either clomiphene citrate or gonadotropins or in the management of PCOS

Diet

When considering a specific diet in the setting of anovulation, the principal focus must be in reference to the endocrinologic and metabolic derangements observed in PCOS. Therefore, a well-structured low-carbohydrate/low-cholesterol regimen is imperative because of the insulin resistance and cardiovascular risks commonly occurring in these patients.

The effectiveness of organized weight loss programs such as Weight Watchers, Curves, or Jenny Craig has been well documented to improve the recidivism rate in overweight patients attempting to lose weight when done in conjunction with counseling and support group initiatives.

Activity

Cardiovascular exercise helps offset the inherent risks associated with PCOS.

Weight-bearing exercise should be recommended for patients with hypoestrogenic states, such as premature ovarian failure, when estrogen replacement is a contraindicated.

Medication

Medical therapy of anovulation should be directed at reversal of the primary underlying cause and tailored to the individual patient.

Ovulation stimulators

Used for ovulation induction.

Clomiphene citrate (Serophene, Clomid, Milophene)

Stimulates release of pituitary gonadotropins. Acts as an antiestrogen to decrease negative estrogen feedback on hypothalamus. In addition, may have effects on pituitary gland and ovaries and can induce ovulation in women with hypothalamic amenorrhea. Improves folliculogenesis and, therefore, ovarian function during luteal phase.

Dosing

Adult

50-100 mg PO qd for 5 d; not to exceed 6 mo

Pediatric

Not established

Interactions

Danazol may reduce response

Contraindications

Documented hypersensitivity; liver disease; abnormal uterine bleeding; uncontrolled thyroid or adrenal dysfunction

Precautions

Pregnancy

X - Contraindicated; benefit does not outweigh risk

Precautions

Visual symptoms and abdominal pain may occur

Thyroid products

Used to correct hypothyroidism.

Levothyroxine (Synthroid, Levoxyl, Levothroid)

If luteal phase dysfunction is caused by hypothyroidism, correction of endocrine disease results in normal luteal phase.

Dosing

Adult

12.5-50 mcg PO qd; increase by 25-50 mcg/d q2-4wk to maximum 100-200 mcg/d

Pediatric

Neonate to 6 months: 25-50 mcg PO qd
6-12 months: 50-75 mcg PO qd
1-5 years: 75-100 mcg PO qd
6-12 years: 100-150 mcg PO qd
>12 years: 150 mcg PO qd

Interactions

Cholestyramine may decrease liothyronine absorption; estrogens may decrease response to thyroid hormone therapy in patients with nonfunctioning thyroid glands; effect of anticoagulants increased when administered with liothyronine; activity of some beta-blockers may decrease when hypothyroid patient is converted to a euthyroid state

Contraindications

Documented hypersensitivity; uncorrected adrenal insufficiency

Precautions

Pregnancy

A - Fetal risk not revealed in controlled studies in humans

Precautions

Caution in angina pectoris or cardiovascular disease; periodically monitor thyroid status

Oral contraceptives

Used for hormone replacement.

Ethinyl estradiol and norethindrone (Ortho-Novum, Ovcon 35, Ovcon 50)

In young females, low-dose PO contraception generally is an excellent method of hormone replacement. Any low-dose combination pill with 35 mcg of ethinyl estradiol or less or any progestin is appropriate. Also useful because, on occasion, these women may spontaneously ovulate and become pregnant.

Dosing

Adult

Schedule 1 (Sunday starter): Begin dose on first Sunday after onset of menstruation or on Sunday if menstrual period starts on Sunday
21-tab package: 1 tab PO qd for 21 d followed by 7 d off medication; new course begins on 8th d after taking last tab
28-tab package: 1 tab PO qd without interruption
Schedule 2 (day 1 starter): Start dose on day 1 of menstrual cycle
21-tab package: 1 tab PO qd for 21 d followed by 7 d off medication; begin new course on day 8 after taking last tab; continue dosing cycle if 1 period is missed; pregnancy test required if 2 periods are missed

Pediatric

Not established

Interactions

Phenobarbital, phenytoin, paramethadione, carbamazepine, troglitazone, rifampicin, and griseofulvin induce enzymes that decrease levels of contraceptive steroids; PO anticoagulants may increase thromboembolic potential; antibiotics may alter GI flora and cause a reduction in absorption of PO contraceptives, which may reduce efficacy

Contraindications

Documented hypersensitivity; endometrial and hepatic cancer; thromboembolic disorders; undiagnosed vaginal bleeding; smokers >35 y; cardiovascular disease

Precautions

Pregnancy

X - Contraindicated; benefit does not outweigh risk

Precautions

Caution in patients diagnosed with hepatic impairment, migraine, seizure disorders, cerebrovascular disorders, breast cancer, or thromboembolic disease

Ethinyl estradiol/norgestimate (Ortho-Prefest, Ortho TriCyclen, Ortho-Cyclen)

In young females, low-dose PO contraception generally is an excellent method of hormone replacement. Any low-dose combination pill with 35 mcg of ethinyl estradiol or less or any progestin is appropriate. Also useful because, on occasion, these women may spontaneously ovulate and become pregnant.

Dosing

Adult

Schedule 1 (Sunday starter):
Begin dose on first Sunday after onset of menstruation; start Sunday if menstrual period starts on Sunday
21-tab package: 1 tab PO qd for 21 d followed by 7 d off medication; new course begins on day 8 after taking last tab 28-tab package: 1 tab PO qd without interruption
Schedule 2 (day 1 starter): Start dose on day 1 of menstrual cycle
21-tab package: 1 tab PO qd for 21 d followed by 7 d off medication; begin new course on day 8 after taking last tab; continue dosing cycle if 1 period is missed; pregnancy test required if 2 periods are missed

Pediatric

Not established

Interactions

Phenobarbital, phenytoin, paramethadione, carbamazepine, troglitazone, rifampicin, and griseofulvin induce enzymes that decrease levels of contraceptive steroids; PO anticoagulants may increase thromboembolic potential; antibiotics may alter GI flora and cause a reduction in absorption of PO contraceptives, which may reduce efficacy

Contraindications

Documented hypersensitivity; endometrial and hepatic cancer; thromboembolic disorders; undiagnosed vaginal bleeding; smokers >35 y; cardiovascular disease

Precautions

Pregnancy

X - Contraindicated; benefit does not outweigh risk

Precautions

Caution in patients diagnosed with hepatic impairment, migraine, seizure disorders, cerebrovascular disorders, breast cancer, or thromboembolic disease

Bisphosphonate derivatives

Analogs of pyrophosphate and act by binding to hydroxyapatite in bone matrix, thereby inhibiting dissolution of crystals. Prevent osteoclast attachment to the bone matrix and osteoclast recruitment and viability.

Alendronate (Fosamax)

Inhibits bone resorption via actions on osteoclasts or osteoclast precursors. Used to treat osteoporosis in both men and women. May reduce bone resorption and incidence of fracture at spine, hip, and wrist by approximately 50%. Should be taken with a large glass of water at least 30 min before eating and drinking to maximize absorption. Because of possible esophageal irritation, patients must remain upright after taking the medication. Since it is renally excreted, not recommended in patients with moderate-to-severe renal insufficiency (ie, CrCl <30 mL/min or serum Cr > 3 mg/dL); use in perirenal transplantation is limited.

Dosing

Adult

Prophylaxis: 5 mg PO qd; alternatively, 35 mg PO qwk
Treatment: 10 mg PO qd; alternatively, 70 mg PO qwk

Pediatric

Not established

Interactions

None reported

Contraindications

Documented hypersensitivity; hypocalcemia; abnormalities of the esophagus; inability to stand upright for 30 min

Precautions

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

Must be taken at least 30 min before first food, beverage, or medication of the day and should be taken with large amounts of water; caution in renal impairment

Oral antidiabetic agents

May increase glucose uptake in peripheral tissues.

Metformin (Glucophage)

Reduces hepatic glucose output, decreases intestinal absorption of glucose, and increases glucose uptake in the peripheral tissues (muscle and adipocytes). Major drug used in obese patients who have type 2 diabetes mellitus.

Dosing

Adult

Initial: 500 mg PO bid
Maintenance: 850 mg PO tid

Pediatric

Not established

Interactions

Diuretics, thyroid products, PO contraceptives, phenytoin, calcium channel–blocking drugs; phenothiazines may decrease effects; cimetidine may increase levels

Contraindications

Documented hypersensitivity; acute myocardial infarction; septicemia; renal disease

Precautions

Pregnancy

B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals

Precautions

Caution in renal insufficiency; discontinue therapy before performing any surgical procedures; impaired liver function

Antiandrogens

May inhibit androgen feedback on pituitary gland.

Finasteride (Proscar, Propecia)

Blocks conversion of testosterone to its more active metabolite, dihydrotestosterone. More effective when used in combination with OCPs.

Dosing

Adult

1 mg PO qd

Pediatric

Not established

Interactions

None reported

Contraindications

Documented hypersensitivity; lactation; childhood

Precautions

Pregnancy

X - Contraindicated; benefit does not outweigh risk

Precautions

Minimum of 6 mo treatment necessary to determine response; caution in liver function abnormalities; monitor patients with severely diminished urinary flow for obstructive uropathy (may not be candidates for this therapy)

Spironolactone (Aldactone)

Aldosterone antagonist that inhibits ovarian and adrenal production of androgens. Competes with dihydrotestosterone binding at hormone receptor sites on hair follicle cells. Also reduces 17alpha-hydroxylase activity, lowering plasma levels of testosterone and androstenedione.

Dosing

Adult

200 mg/d PO qd or divided bid

Pediatric

Not established

Interactions

May decrease effect of anticoagulants; potassium and potassium-sparing diuretics may increase toxicity

Contraindications

Documented hypersensitivity; anuria; renal failure; hyperkalemia

Precautions

Pregnancy

D - Fetal risk shown in humans; use only if benefits outweigh risk to fetus

Precautions

Caution in renal and hepatic impairment; electrolytes and blood pressure should be monitored for first few weeks of therapy to be certain hypotension and hyperkalemia do not occur

Glucocorticoids

May be used to correct adrenal insufficiency.

Fludrocortisone (Florinef)

Partial replacement therapy for primary and secondary adrenocortical insufficiency.

Dosing

Adult

0.1 mg PO qd

Pediatric

0.05-0.1 mg PO qd

Interactions

Antagonizes effects of anticholinergics; rifampin, hydantoins, and barbiturates decrease effects; decreases salicylate levels

Contraindications

Documented hypersensitivity; systemic fungal infections

Precautions

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

Taper dose gradually when therapy is discontinued; caution in Addison disease, potassium loss, and sodium retention

Antifungal agents

Inhibit a variety of cytochrome P-450 enzymes, including 11beta-hydroxylase and 17-alpha-hydroxylase, which in turn, inhibit steroid synthesis.

Ketoconazole (Nizoral)

Inhibits steroid synthesis at the level of 17-alpha-hydroxylase/17,20-lyase, a key enzyme in sex steroid production. Also inhibits testosterone binding to its binding globulin. In some cases, especially in children with markedly advanced bone age, a rapid decrease in sex hormone levels may trigger true central puberty. In this event, add GnRH analogs to the treatment regimen.

Dosing

Adult

200-400 mg PO bid/tid

Pediatric

Not established

Interactions

Isoniazid may decrease bioavailability; coadministration decreases effects of either rifampin or ketoconazole; may increase effect of anticoagulants; may increase toxicity of corticosteroids and cyclosporine (cyclosporine dosage can be adjusted); may decrease theophylline levels; decreases metabolism of repaglinide, thus increasing serum levels and effects

Contraindications

Documented hypersensitivity; fungal meningitis

Precautions

Pregnancy

X - Contraindicated; benefit does not outweigh risk

Precautions

Hepatotoxicity may occur; may reversibly decrease corticosteroid serum levels (adverse effects avoided with dose of 200-400 mg/d); administer antacid, anticholinergics, or H2 blockers at least 2 h after taking ketoconazole

Dopamine agonists

Directly stimulate postsynaptic dopamine receptors. The dopaminergic neurons in the tuberoinfundibular process modulate the secretion of prolactin from the anterior pituitary by secreting a prolactin inhibitory factor (believed to be dopamine).

Pergolide was withdrawn from the US market March 29, 2007, because of heart valve damage resulting in cardiac valve regurgitation. It is important not to abruptly stop pergolide. Health care professionals should assess patients' need for dopamine agonist (DA) therapy and consider alternative treatment. If continued treatment with a DA is needed, another DA should be substituted for pergolide. For more information, see FDA MedWatch Product Safety Alert and Medscape Alerts: Pergolide Withdrawn From US Market.

Pergolide (Permax)

Pergolide withdrawn from US market. Inhibits secretion of prolactin (PRL); causes a transient rise in serum concentrations of GH and decreases serum concentrations of LH.

Dosing

Adult

Administered at initial dose of 25 g/d, and then at 50 g/d with gradual dose escalation, depending on extent of serum PRL normalization

Pediatric

Not established

Interactions

Antagonists such as the neuroleptics phenothiazine, butyrophenones, thioxanthenes, and metoclopramide may diminish effectiveness of pergolide, a dopamine agonist; because pergolide mesylate is more than 90% bound to plasma proteins, exercise caution if coadministered with other drugs known to affect protein binding

Contraindications

Documented hypersensitivity

Precautions

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

May cause valvular heart disease (yearly echocardiograms recommended for patients on chronic therapy); inhibits secretion of prolactin; causes transient rise in serum concentrations of growth hormone and decrease in serum concentrations of luteinizing hormone; adverse effects include nausea, hypotension, hallucinations, and somnolence; use caution in patients who have been treated for cardiac dysrhythmias; may cause or exacerbate preexisting states of confusion and hallucinations or dyskinesia

Progestins

May be used for endometrial stabilization and organization of basal layer in chronic anovulation.

Medroxyprogesterone acetate (Provera, Cycrin, Depo-Provera)

Derivative of progesterone. Androgenic and anabolic effects have been noted, but apparently is devoid of significant estrogenic activity. Parenterally administered dosage form inhibits gonadotropin production, which in turn, prevents follicular maturation and ovulation. Available data indicate that this does not occur when the usually recommended PO dose is administered qd. When orally administered in the recommended doses to women adequately exposed to exogenous or endogenous estrogen, transforms the proliferative endometrium into a secretory one.

Dosing

Adult

10 mg PO qd for first 10 d of menstrual cycle

Pediatric

Not recommended

Interactions

Aminoglutethimide may decrease effects by increasing hepatic metabolism of medroxyprogesterone

Contraindications

Documented hypersensitivity; cerebral apoplexy; undiagnosed vaginal bleeding; thrombophlebitis; liver dysfunction

Precautions

Pregnancy

X - Contraindicated; benefit does not outweigh risk

Precautions

Caution in asthma, depression, renal or cardiac dysfunction, or thromboembolic disorders

Estrogens

May be used to build endometrial lining in acute and chronic anovulation.

Estrogens, conjugated/equine (Premarin)

May be used for restoration of regular menstrual cycles, which may prevent endometrial hyperplasia associated with anovulation. Improvements of hyperandrogenic effects occur in 60-100% of women but usually require a minimum of 6-12 mo of use. A pregnancy test should be performed before initiating therapy. If the woman has had no menstrual period for 3 mo, withdrawal bleeding should be induced by administration of 5-10 mg of medroxyprogesterone acetate (Provera) qd for 10 d; therapy is then begun with OCPs.

Dosing

Adult

0.05 mg PO qd/tid

Pediatric

Not established

Interactions

May reduce hypoprothrombinemic effects of anticoagulants; estrogen levels may be reduced with coadministration of barbiturates, rifampin, and other agents that induce hepatic microsomal enzymes; an increase in corticosteroid levels may occur when administered concurrently with ethinyl estradiol; use of ethinyl estradiol with hydantoins may cause spotting, breakthrough bleeding, and reduce contraceptive efficacy; increase in fluid retention caused by estrogen intake may reduce seizure control; antibiotics may alter GI flora and cause a reduction in absorption of PO contraceptives, which may reduce efficacy

Contraindications

Documented hypersensitivity; thrombophlebitis; undiagnosed vaginal bleeding

Precautions

Pregnancy

X - Contraindicated; benefit does not outweigh risk

Precautions

Exercise caution in patients diagnosed with hepatic impairment, migraine, seizure disorders, cerebrovascular disorders, breast cancer, or thromboembolic disease

Nonsteroidal anti-inflammatory drugs

Reduce blood loss by 30-50% in cases of anovulatory bleeding.

Ibuprofen (Advil, Motrin, Excedrin IB)

Used for reduction in uterine bleeding and dysmenorrhea associated with anovulatory cycles. Blocks formation of prostacyclin, an antagonist of thromboxane, a substance that accelerates platelet aggregation and initiates coagulation. Because NSAIDs inhibit blood prostacyclin formation, they might effectively decrease uterine blood flow.

Dosing

Adult

200-400 mg PO q4-6h while symptoms persist; not to exceed 3.2 g/d

Pediatric

<12 years: Not established
>12 years: Administer as in adults

Interactions

Coadministration with aspirin increases risk of inducing serious NSAID-related adverse effects; probenecid may increase concentrations and, possibly, toxicity; may decrease effect of hydralazine, captopril, and beta-blockers; may decrease diuretic effects of furosemide and thiazides; may increase PT when taking anticoagulants (instruct patients to watch for signs of bleeding); may increase risk of methotrexate toxicity; phenytoin levels may be increased when administered concurrently

Contraindications

Documented hypersensitivity; peptic ulcer disease; recent GI bleeding or perforation; renal insufficiency; high risk of bleeding

Precautions

Pregnancy

B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals

D - Fetal risk shown in humans; use only if benefits outweigh risk to fetus

Precautions

Caution in congestive heart failure, hypertension, and decreased renal and hepatic function; caution in coagulation abnormalities or during anticoagulant therapy

Follow-up

Further Inpatient Care

• Inpatient care is directly related to the cause of anovulation.
• Because of the menstrual irregularities associated with anovulation, anemia is a concern and must be treated with allogeneic blood transfusion if blood parameters fall below critical levels. Intravenous estrogen (Premarin) or high-dose combined oral contraceptives may be needed to ameliorate or terminate the acute bleeding episode. Dilation and curettage should never be the first-line treatment in this clinical setting; however, in the case of intractable bleeding, it may be the only alternative. Subtotal or total hysterectomy is rarely, if ever, necessary.

Further Outpatient Care

• Long-term health consequences, depending on their etiologic origin, include an increased risk for obesity, diabetes mellitus, heart disease, dyslipidemia, hypertension, endometrial hyperplasia, and infertility, and treatment must be focused on addressing these health concerns in addition to the primary causes (ie, PCOS). Therefore, aggressive preventative health care interventions are warranted, including interventions that lower cardiovascular risk factors through diet, exercise, and judicious use of statin medications when appropriate, as well as endometrial biopsy in the setting of chronic irregular bleeding regardless of age for the diagnosis of endometrial hyperplasia. Assessment must be continued at routine intervals (eg, every 4-6 mo).

Complications

• Endometrial hyperplasia
• Insulin resistance or type 2 diabetes mellitus
• Cardiovascular disease
• Venous thromboembolism secondary to estrogen therapy
• Electrolyte derangements (anorexia nervosa)
• Arrhythmias (anorexia nervosa)

Prognosis

• Prognosis is generally favorable with appropriate and timely treatment.

Patient Education

• Education for these patients should focus on an understanding of the underlying disorders to ensure compliance with both medical therapy and lifestyle modifications.
• For excellent patient education resources, visit eMedicine's Eating Disorders Center and Women's Health Center. Also, see eMedicine's patient education article, Anorexia Nervosa.

Miscellaneous

Medicolegal Pitfalls

• Diagnosis and treatment of PCOS must begin in a timely fashion in order to help reduce the morbidity and mortality from diabetes mellitus and cardiovascular disease. There is a genetic component to PCOS, and it is usually seen in first- and second-degree relatives.
• Patients with chronic anovulation are at increased risk for endometrial hyperplasia and malignancy, and endometrial sampling is imperative.
• Food and Drug Administration (FDA) approval has not been obtained for any of the treatments usually used in the treatment of hirsutism. Patients must be aware of the risks involved in using these medications.

Multimedia

Media file 1: Anovulation. Polycystic ovary. Courtesy of Jairo E. Garcia, MD.

Media file 2: Anovulation. On the left is an unaffected patient aged 12 years. On the right is the same patient aged 13 years after developing Cushing disease.

Media file 3: Anovulation. Left adrenal mass discovered incidentally.

Media file 4: Anovulation. MRI showing a nonenhancing area in the pituitary consistent with a microadenoma in a patient with hyperprolactinemia.

References

1. Speroff L, Glass RH, Kase NG. Anovulation and the polycystic ovary syndrome. In: Clinical Gynecologic Endocrinology and Infertility. Philadelphia, PA: Lippincott Williams & Wilkins; 1999:487-513.

2. Spence JE. Anovulation and monophasic cycles. Ann N Y Acad Sci. Jun 17 1997;816:173-6. [Medline].

3. Yen SC, Jaffe RB, Barbieri RL. Chronic anovulation due to CNS-hypothalamic-pituitary dysfunction. In: Reproductive Endocrinology: Physiology, Pathophysiology and Clinical Management. 4^th ed. London, England: Elsevier Science; 1999.

4. Franks S, Mason H, White D, Willis D. Etiology of anovulation in polycystic ovary syndrome. Steroids. May-Jun 1998;63(5-6):306-7. [Medline].

5. Rasgon N. The relationship between polycystic ovary syndrome and antiepileptic drugs: a review of the evidence. J Clin Psychopharmacol. Jun 2004;24(3):322-34. [Medline].

6. Haiman CA, Pike MC, Bernstein L, et al. Ethnic differences in ovulatory function in nulliparous women. Br J Cancer. Feb 1 2002;86(3):367-71. [Medline].

7. Laven JS, Imani B, Eijkemans MJ, Fauser BC. New approach to polycystic ovary syndrome and other forms of anovulatory infertility. Obstet Gynecol Surv. Nov 2002;57(11):755-67. [Medline].

8. Dunaif A. Hyperandrogenic anovulation (PCOS): a unique disorder of insulin action associated with an increased risk of non-insulin-dependent diabetes mellitus. Am J Med. Jan 16 1995;98(1A):33S-39S. [Medline].

9. The Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. Jan 2004;81(1):19-25. [Medline].

10. Franks S, Robinson S, Willis DS. Nutrition, insulin and polycystic ovary syndrome. Rev Reprod. Jan 1996;1(1):47-53. [Medline].

11. Pritts EA. Treatment of the infertile patient with polycystic ovarian syndrome. Obstet Gynecol Surv. Sep 2002;57(9):587-97. [Medline].

12. Legro R. Polycystic ovary syndrome. In: Precis, Reproductive Endocrinology: An Update in Obstetrics and Gynecology. 2^nd ed. American College of Obstetricians & Gynecologists; 2002:85-89.

13. Thatcher S. Diagnosis of polycystic ovary syndrome. Female patient. 2004;29:33-41.

14. Futterweit W. Polycystic ovary syndrome: clinical perspectives and management. Obstet Gynecol Surv. Jun 1999;54(6):403-13. [Medline].

15. Bergfeld WF. Hirsutism in women. Effective therapy that is safe for long-term use. Postgrad Med. Jun 2000;107(7):93-4, 99-104. [Medline].

16. Frisch RE, McArthur JW. Menstrual cycles: fatness as a determinant of minimum weight for height necessary for their maintenance or onset. Science. Sep 13 1974;185(4155):949-51. [Medline].

17. Andrico S, Gambera A, Specchia C, et al. Leptin in functional hypothalamic amenorrhoea. Hum Reprod. Aug 2002;17(8):2043-8. [Medline].

18. Warren MP, Vu C. Central causes of hypogonadism--functional and organic. Endocrinol Metab Clin North Am. Sep 2003;32(3):593-612. [Medline].

19. Yen SC, Jaffe RB, Barbieri RL. Chronic anovulation caused by peripheral endocrine disorders. In: Reproductive Endocrinology: Physiology, Pathophysiology and Clinical Management. 4^th ed. London, England: Elsevier Science; 1999.

20. Warren MP, Perlroth NE. The effects of intense exercise on the female reproductive system. J Endocrinol. Jul 2001;170(1):3-11. [Medline].

21. Mestman JH. Endocrine diseases in pregnancy. In: Gabbe S, Neibyl JR, eds. Obstetrics Normal and Problem Pregnancies. 4th ed. New York, NY: Churchill Livingstone; 2002:1117-8.

22. Goswami R, Kochupillai N, Crock PA, Jaleel A, Gupta N. Pituitary autoimmunity in patients with Sheehan's syndrome. J Clin Endocrinol Metab. Sep 2002;87(9):4137-41. [Medline].

23. Velduis JD, Weiss J, Mauras N, et al. Appraising endocrine pulse signals at low circulating hormone concentrations: use of regional coefficients of variation in the experimental series to analyze pulsatile luteinizing hormone release. Pediatr Res. Jul 1986;20(7):632-7. [Medline].

24. Bills DC, Meyer FB, Laws ER, et al. A retrospective analysis of pituitary apoplexy. Neurosurgery. Oct 1993;33(4):602-8; discussion 608-9. [Medline].

25. Abe T, Ludecke DK. Transnasal surgery for prolactin-secreting pituitary adenomas in childhood and adolescence. Surg Neurol. Jun 2002;57(6):369-78; discussion 378-9. [Medline].

26. Molitch ME. Disorders of prolactin secretion. Endocrinol Metab Clin North Am. Sep 2001;30(3):585-610. [Medline].

27. Goldman L, Ausiello D. Obesity. In: Cecil Textbook of Medicine. 22^nd ed. 2004:1346.

28. ACOG Committee on Practice Bulletins, American College of Obstetricians and Gynecologists. ACOG practice bulletin: management of anovulatory bleeding. Int J Gynaecol Obstet. Mar 2001;72(3):263-71. [Medline].

29. Akande EO. Plasma concentration of gonadotrophins, oestrogen and progesterone in hypothyroid women. Br J Obstet Gynaecol. Jul 1975;82(7):552-6. [Medline].

30. Akande EO, Hockaday TD. Plasma concentration of gonadotrophins, oestrogens and progesterone in thyrotoxic women. Br J Obstet Gynaecol. Jul 1975;82(7):541-51. [Medline].

31. Bankowski BJ, Zacur HA. Dopamine agonist therapy for hyperprolactinemia. Clin Obstet Gynecol. Jun 2003;46(2):349-62. [Medline].

32. Barbieri RL. Metformin for the treatment of polycystic ovary syndrome. Obstet Gynecol. Apr 2003;101(4):785-93. [Medline].

33. Baumann EE, Rosenfeld RL. Polycystic ovary syndrome in adolescence. Endocrinologist. 2002;12:333-48.

34. Ben-Rafael Z, Orvieto R. Polycystic ovary syndrome: a single gene mutation or an evolving set of symptoms. Curr Opin Obstet Gynecol. Jun 2000;12(3):169-73. [Medline].

35. Boccuzzi G, Angeli A, Bisbocci D, Fonzo D, Giadano GP, Ceresa F. Effect of synthetic luteinizing hormone releasing hormone (LH-RH) on the release of gonadotropins in Cushing's disease. J Clin Endocrinol Metab. May 1975;40(5):892-5. [Medline].

36. Bray GA, York DA. Clinical review 90: Leptin and clinical medicine: a new piece in the puzzle of obesity. J Clin Endocrinol Metab. Sep 1997;82(9):2771-6. [Medline].

37. Brenner PF. Differential diagnosis of abnormal uterine bleeding. Am J Obstet Gynecol. Sep 1996;175(3 Pt 2):766-9. [Medline].

38. Camargo CA. Hypothyroidism and goiter during pregnancy. In: Brody SA, Ueland K, eds. Endocrine Disorders of Pregnancy. Stamford, Conn: Appleton & Lange; 1989:1989:165-76.

39. Campo S. Ovulatory cycles, pregnancy outcome and complications after surgical treatment of polycystic ovary syndrome. Obstet Gynecol Surv. May 1998;53(5):297-308. [Medline].

40. Carmina E, Lobo RA. Polycystic ovary syndrome (PCOS): arguably the most common endocrinopathy is associated with significant morbidity in women. J Clin Endocrinol Metab. Jun 1999;84(6):1897-9. [Medline].

41. Clark RA, Mulligan K, Stamenovic E, et al. Frequency of anovulation and early menopause among women enrolled in selected adult AIDS clinical trials group studies. J Infect Dis. Nov 15 2001;184(10):1325-7. [Medline].

42. Cotran RS, Kumar V, Collins T. Anovulation. In: Robbin's Pathologic Basis of Disease. 6^th ed. Elsevier Science; 1999:1056.

43. Daniels GH. Thyroid disease and pregnancy: a clinical overview. Endocrinol Pract. 1995;1:287-301.

44. del Pozo E, Wyss H, Tollis G, et al. Prolactin and deficient luteal function. Obstet Gynecol. Mar 1979;53(3):282-6. [Medline].

45. Edwards CR, Forsyth IA, Besser GM. Amenorrhoea, galactorrhoea, and primary hypothyroidism with high circulating levels of prolactin. Br Med J. Aug 1971;3(772):462-4. [Medline].

46. Franks S, Gharani N, Waterworth D, et al. Genetics of polycystic ovary syndrome. Mol Cell Endocrinol. Oct 25 1998;145(1-2):123-8. [Medline].

47. Franks S, McCarthy M. Genetics of ovarian disorders: polycystic ovary syndrome. Rev Endocr Metab Disord. Mar 2004;5(1):69-76. [Medline].

48. Frisch RE, Wyshak G, Vincent L. Delayed menarche and amenorrhea in ballet dancers. N Engl J Med. Jul 3 1980;303(1):17-9. [Medline].

49. Goldsmith R, Sturgis S, Lerman J, et al. The menstrual pattern in thyroid disease. J Clin Endocrinol Metab. Jul 1952;12(7):846-55. [Medline].

50. Golovleva LA, Golovlev EL, Ganbarov KhG, Skriabin GK. [Role of cosubstrates in the microbiologic oxidation of xylene isomers by a culture of Pseudomonas aeruginosa]. Mikrobiologiia. Jan-Feb 1977;46(1):5-9. [Medline].

51. Hamilton-Fairley D, Taylor A. Anovulation. BMJ. Sep 6 2003;327(7414):546-9. [Medline].

52. Inamasu J, Hori S, Sekine K, Aikawa N. Pituitary apoplexy without ocular/visual symptoms. Am J Emerg Med. Jan 2001;19(1):88-90. [Medline].

53. Knochenhauer ES, Key TJ, Kahsar-Miller M, et al. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab. Sep 1998;83(9):3078-82. [Medline].

54. Malcolm CE, Cumming DC. Does anovulation exist in eumenorrheic women?. Obstet Gynecol. Aug 2003;102(2):317-8. [Medline].

55. Norman RJ. Obesity, polycystic ovary syndrome and anovulation--how are they interrelated?. Curr Opin Obstet Gynecol. Jun 2001;13(3):323-7. [Medline].

56. Norman RJ, Wu R, Stankiewicz MT. 4: Polycystic ovary syndrome. Med J Aust. Feb 2 2004;180(3):132-7. [Medline].

57. Pfeifer SM, Dayal M. Treatment of the adolescent patient with polycystic ovary syndrome. Obstet Gynecol Clin North Am. Jun 2003;30(2):337-52. [Medline].

58. Sabogal JC, Muñoz L. Leptin in obstetrics and gynecology: a review. Obstet Gynecol Surv. Apr 2001;56(4):225-30. [Medline].

59. Sakakura M, Takebe K, Nakagawa S. Inhibition of luteinizing hormone secretion induced by synthetic LRH by long-term treatment with glucocorticoids in human subjects. J Clin Endocrinol Metab. May 1975;40(5):774-9. [Medline].

60. Schlechte J, Sherman B, Halmi N, et al. Prolactin-secreting pituitary tumors in amenorrheic women: a comprehensive study. Endocr Rev. Summer 1980;1(3):295-308. [Medline].

61. Serri O, Chik CL, Ur E, Ezzat S. Diagnosis and management of hyperprolactinemia. CMAJ. Sep 16 2003;169(6):575-81. [Medline].

62. Shangold MM. Athletic amenorrhea. Clin Obstet Gynecol. Sep 1985;28(3):664-9. [Medline].

63. Thomas R, Reid RL. Thyroid disease and reproductive dysfunction: a review. Obstet Gynecol. Nov 1987;70(5):789-98. [Medline].

64. Tolino A, Nicotra M, Romano L, et al. Subclinical hypothyroidism and hyperprolactinemia. Acta Eur Fertil. Sep-Oct 1991;22(5):275-7. [Medline].

65. Tsilchorozidou T, Overton C, Conway GS. The pathophysiology of polycystic ovary syndrome. Clin Endocrinol (Oxf). Jan 2004;60(1):1-17. [Medline].

66. Veldhuis JD, Hammond JM. Endocrine function after spontaneous infarction of the human pituitary: report, review, and reappraisal. Endocr Rev. Winter 1980;1(1):100-7. [Medline].

67. Warren MP, Brooks-Gunn J, Fox RP, et al. Persistent osteopenia in ballet dancers with amenorrhea and delayed menarche despite hormone therapy: a longitudinal study. Fertil Steril. Aug 2003;80(2):398-404. [Medline].

68. Warren MP, Goodman LR. Exercise-induced endocrine pathologies. J Endocrinol Invest. Sep 2003;26(9):873-8. [Medline].

69. Warren MP, Vu C. Central causes of hypogonadism--functional and organic. Endocrinol Metab Clin North Am. Sep 2003;32(3):593-612. [Medline].

70. Wilansky DL, Greisman B. Early hypothyroidism in patients with menorrhagia. Am J Obstet Gynecol. Mar 1989;160(3):673-7. [Medline].

71. Wilson JD, Foster DW, Kronenberg HM. Disorders of the ovaries and female reproductive tract. In: Williams Textbook of Endocrinology. 10^th ed. WB Saunders Co; 2003:751-817.

72. Winters SJ, Berga SL. Gonadal dysfunction in patients with thyroid disorders. Endocrinologist. 1997;7:167-73.

73. Yen SC, Jaffe RB, Barbieri RL. Polycystic ovary syndrome: Hyperandrogenic chronic anovulation. In: Reproductive Endocrinology: Physiology, Pathophysiology and Clinical Management. 4^th ed. London, England: Elsevier Science; 1999.

74. Zakarija M, McKenzie JM. Pregnancy-associated changes in the thyroid-stimulating antibody of Graves' disease and the relationship to neonatal hyperthyroidism. J Clin Endocrinol Metab. Nov 1983;57(5):1036-40. [Medline].

75. Zawadski JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome. In: Givens J, Haseltine F, Merriman G. The Polycystic Ovary Syndrome. Cambridge, MA: Blackwell Scientific; 1992:377-384.

Keywords

dysfunctional uterine bleeding, DUB, amenorrhea, chronic anovulation, hypogonadotropic hypogonadism, hypergonadotropic hypogonadism, luteinizing hormone, LH, gonadotropin-releasing hormone, GnRH, polycystic ovary syndrome, PCOS, follicle-stimulating hormone, FSH, hypothalamic-pituitary-ovarian axis, HPO axis

Contributor Information and Disclosures

Author

Armando E Hernandez-Rey, MD, Consulting Staff, Fertility and IVF Center of Miami
Armando E Hernandez-Rey, MD is a member of the following medical societies: American Association of Gynecologic Laparoscopists, American College of Obstetricians and Gynecologists, American Medical Association, American Society for Reproductive Medicine, Society for Gynecologic Investigation, Society for Reproductive Endocrinology and Infertility, and Society of Laparoendoscopic Surgeons
Disclosure: Nothing to disclose.

Coauthor(s)

Krystene I Boyle, MD, Staff Physician, Department of Obstetrics and Gynecology, University Hospital of New Jersey Medical School
Krystene I Boyle, MD is a member of the following medical societies: Sigma Xi
Disclosure: Nothing to disclose.

Cassandra Blot, MD, Staff Physician, Department of Obstetrics and Gynecology, Robert Wood Johnson University Hospital
Cassandra Blot, MD is a member of the following medical societies: American College of Obstetricians and Gynecologists
Disclosure: Nothing to disclose.

Peter G McGovern, MD, Associate Professor and Director, Department of Obstetrics, Gynecology, and Women's Health, Division of Reproductive Endocrinology and Infertility, UMDNJ-New Jersey Medical School
Disclosure: Nothing to disclose.

Medical Editor

Gerard S Letterie, DO, Associate Clinical Professor, Medical Director of In-vitro Fertilization Lab, Department of Obstetrics and Gynecology, Virginia Mason Medical Center, University of Washington
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: Nothing to disclose.

Managing Editor

Carl V Smith, MD, The Distinguished Chris J and Marie A Olson Chair of Obstetrics and Gynecology, Professor, Department of Obstetrics and Gynecology, University of Nebraska Medical Center
Carl V Smith, MD is a member of the following medical societies: American College of Obstetricians and Gynecologists, American Institute of Ultrasound in Medicine, American Medical Association, Arkansas Medical Society, Association of Professors of Gynecology and Obstetrics, Central Association of Obstetricians and Gynecologists, Council of University Chairs of Obstetrics and Gynecology, Nebraska Medical Association, and Society for Maternal-Fetal Medicine
Disclosure: Nothing to disclose.

CME Editor

Frederick B Gaupp, MD, Consulting Staff, Department of Family Practice, Assumption Community Hospital
Frederick B Gaupp, MD is a member of the following medical societies: American Academy of Family Physicians
Disclosure: Nothing to disclose.

Chief Editor

Bryan D Cowan, MD, Professor and Chairman, Department of Obstetrics and Gynecology, University of Mississippi College of Medicine; Consulting Staff, Department of Obstetrics and Gynecology, Veterans Affairs Medical Center; Medical Director, Wiser Hospital for Women, University of Mississippi Medical Center
Bryan D Cowan, MD is a member of the following medical societies: American Association of Gynecologic Laparoscopists, American College of Obstetricians and Gynecologists, American Gynecological and Obstetrical Society, American Medical Association, American Society for Reproductive Medicine, Association of Professors of Gynecology and Obstetrics, Central Association of Obstetricians and Gynecologists, Endocrine Society, Sigma Xi, Society for Assisted Reproductive Technologies, Society for Gynecologic Investigation, Society for the Study of Reproduction, and Society of Laparoendoscopic Surgeons
Disclosure: Nothing to disclose.

See Medscape's Ob/Gyn and Women's Health.

© 1994- by Medscape.
All Rights Reserved
(http://www.medscape.com/public/copyright)